Bayer’s factor XIa inhibitor slashed the risk of recurrent stroke in a late-stage trial in certain patients, breathing new life into a class of drugs that has suffered a string of high-profile failures.
The unexpected …
The FDA has started a priority review of Otsuka’s triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.
Tenpoint Therapeutics landed an FDA approval for its presbyopia eye drop on Wednesday, entering a tricky commercial landscape for therapeutic alternatives to reading glasses and
ChenMed CEO Chris Chen said the primary care chain isn’t encouraging the use of GLP-1 drugs for weight loss after finding the medications led to
Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to
Veradermics, a biotech in late-stage testing with an oral version of Rogaine, is looking to raise $181.8 million in net proceeds from its proposed IPO.
Bayer’s factor XIa inhibitor slashed the risk of recurrent stroke in a late-stage trial in certain patients, breathing new life into a class of drugs that has suffered a string of high-profile failures.
The unexpected …